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index date or during follow-up or receiving rivaroxaban at a dose and/
or schedule inconsistent with approved labeling were excluded. Since
analysis of only anonymized data was performed, this study was
exempted from institutional review board oversight.
Potentially eligible rivaroxaban (n = 1046) and VKA (n = 4062) pa-
tients were 1:1 propensity score-matched to generate an analysis cohort
with minimal differences in baseline characteristics [4]. Residual differ-
ences in characteristics betweenmatched cohortswere assessed by calcu-
lating standardized differences, with differences of b10% considered
balanced [5]. Patients were matched on age, gender, CHA2DS2-VASc
risk score and the number of co-morbidities.
The a priori primary endpoint was the time-to-composite of ische-Rivaroxaban has been shown effective in reducing the risk of stroke
in patients with non-valvular atrial ﬁbrillation (NVAF) in a randomized
controlled trial (RCT) [1]. However, scarce data comparing real-life out-
comes between rivaroxaban and vitamin K antagonist (VKA) users with
NVAF are available [2]. The objective of the ‘REal-LIfe Evidence on stroke
prevention in patients with atrial Fibrillation’ (RELIEF) study was to
compare the effectiveness of newly-initiated rivaroxaban or VKA thera-
py among NVAF patients in Germany.
The RELIEF study was a retrospective study performed in German
outpatients using data from the Primary Care Physician panel
(representing 1205 practices/1409 physicians) of a patient-level longitu-
dinal electronic medical record (EMR) database (IMS Disease Analyzer)
[3]. To be included, patients had to be newly-initiated on rivaroxaban
or a VKA between 1/2012 and 10/2013, ≥18 years-of-age on the day of
the ﬁrst qualifying anticoagulant prescription (index date), have a diag-
nosis of NVAF on the index date or any time during the 365-days prior,
have follow-up ≥360-days after the index date and exhibit evidence of
patient activity during the 90-days prior to the index date. A 12-month
pre-index period was used to identify patient co-morbidities and prior
medication use. Patients with valvular AF, experiencing a prior cardio-
vascular event as deﬁned in the composite endpoint, receiving an oralrsity of Connecticut, 69 North
eman).
land Ltd. This is an open access articlanticoagulant (OAC) before the index date, prescribed N1 OAC on the
mic stroke, transient ischemic attack, intracerebral hemorrhage, other
non-traumatic intracranial hemorrhage including subdural hemorrhage
and myocardial infarction within one-year of treatment initiation. The
incidence of events was reported as the number of events/100 person-
years and calculated as the number of patients with ≥1 documented
event divided by the entire time at risk of the respective cohort.
Baseline characteristics of patients were analyzed using descriptive
statistics. A Cox proportional hazard analysiswas performed to calculate
the hazard ratio (HR)with 95% conﬁdence intervals (CIs) for developing
the primary endpoint between the matched cohorts within the ﬁrst-
year after treatment initiation. Statistical analyses were performed
using SAS v9.3 (SAS Inc., Cary, NC, USA).
Following propensity score-matching, 1039 rivaroxaban and 1039
VKA users were matched. Characteristics of the cohorts are in Table 1.
No characteristic exhibited a standardized difference N10%.
In total, 57 eventswere identiﬁed during follow-up (Table 2). The in-
cidence of the primary endpoint was lower in rivaroxaban compared
with VKA users (1.97 vs. 3.68 events/100 person-years) corresponding
to a hazard ratio of 0.54 (95%CI= 0.31–0.92) in the time-to-event anal-
ysis. Rates of individual endpoints were numerically less frequent in the
rivaroxaban cohort.
This study used real-life EMR data from Germany to compare the ef-
fectiveness of rivaroxaban and VKA therapy in NVAF patients.
Rivaroxaban use was associated with a lower incidence of developing
the primary endpoint, aswell as individual components. The Rivaroxaban
Once Daily Oral Direct Factor Xa Inhibition Comparedwith Vitamin K An-
tagonism for Prevention of Stroke and EmbolismTrial in Atrial Fibrillation
(ROCKET-AF) [1] failed to demonstrate a reduction in ischemic strokee under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1





n (%) n (%)
Age in years, mean (SD) 74.0 (10.7) 74.4 (9.9)
Gender, % male 538 (51.8) 538 (51.8)
Relevant co-morbidities
Hypertension (ICD-10 I10) 835 (80.4) 846 (81.4)
Diabetes mellitus (ICD-10 E10-14) 334 (32.1) 366 (35.2)
Renal failure (N17–19) 110 (10.6) 133 (12.8)
Deep vein thrombosis (ICD-10 I80-82 without I80.0) 81 (7.8) 66 (6.4)
Unstable angina (ICD-10 I20) 76 (7.3) 64 (6.2)
Hyperthyreoidea (ICD-10 E05) 65 (6.3) 61 (5.9)
Pulmonary embolism (ICD-10 I26) 22 (2.1) 30 (2.9)
Congestive heart failure (ICD-10 I50) 29 (2.8) 28 (2.7)
Functional dyspepsia (ICD-10 K30) 21 (2.0) 20 (1.9)
Stroke risk scores
CHADS2 score, mean (SD) 1.7 (1.0) 1.8 (0.9)
CHA2DS2-VASc score, mean (SD) 3.9 (1.5) 3.9 (1.4)
Bleeding risk score
ATRIA modiﬁed⁎, mean (SD) 2.1 (1.7) 2.1 (1.7)
Time period in days between NVAF diagnosis and
start
of OAC treatment (days), mean (SD)
18.5 (47.4) 29.3 (61.7)
History of cardiovascular drug use
Anti-arrhythmics 140 (13.5) 113 (10.9)
Beta blockers 792 (76.2) 795 (76.5)
ACE inhibitors 453 (43.6) 537 (51.7)
ARBs 294 (28.3) 246 (23.7)
Ca channel blockers 311 (29.9) 349 (33.6)
Diuretics 416 (40.0) 484 (46.6)
Anti-platelet drugs 292 (28.1) 258 (24.8)
ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker; Ca =
calcium; ICD-10 = International Classiﬁcation on Diseases-10th revision; SD = standard
deviation; SHI = statutory health insurance; VKA = vitamin K antagonist.
⁎ The ATRIA score was calculated based on ICD-10 codes; because for some conditions
like anemia respective laboratory values were not available.
883Correspondence(HR = 0.94, 95%CI = 0.75–1.17) between rivaroxaban and warfarin
users. There are, however, plausible explanations for the differences in
ﬁndings between these studies. In ROCKET-AF, Western European pa-
tients had a mean time-in-the therapeutic international normalized
ratio (INR) range (TTR) of ~63%; a value similar tomost RCTs [1,6]. How-
ever, a meta-analysis suggests that TTR is 9% (95%CI = 4–14%) lower in
community compared with RCT-treated patients [7]. It is possible that
the TTR in this real-life German population was lower than in ROCKET-
AF; reducing VKA effectiveness. This may have been particularly true in
the ﬁrstmonths of VKA initiation [7], which is consistentwith the shorter
median time-to-event observed with VKA (vs. rivaroxaban) in our study.
Although the IMS database contains INR data; laboratory valueswere not
available for all patients andwe could not formally test this hypothesis. A
second explanation for the favorable relative effectiveness of rivaroxaban
in the real-world is the higher likelihood of discontinuation with VKAsTable 2
Composite endpoint and individual components.
Endpoint
Composite endpoint — incidence per 100 patient years
Median time to primary event (days) in patients with events
Composite endpoint rivaroxaban vs. VKA; hazard ratio (95%CI, p value)
Single endpoints (ﬁrst event) — incidence per 100 patient years⁎
Ischemic stroke (ICD-10 I63)
TIA (ICD-10 G45 without G45.3)
Intracerebral hemorrhage (ICD-10 I61)
Other non-traumatic intracranial hemorrhage including subdural hemorrhage (ICD-10 I
MI (acute and subsequent; ICD-10 I21,I22)
CI = conﬁdence interval; ICD-10 = International Classiﬁcation on Diseases-10th revision; MI =
⁎ One patient in the VKA cohort with more than one single endpoint recorded at the same dcompared with non-VKA OACs [2,8]. Finally, the predominant use of
phenprocoumon in Germany may have played a role.
Laliberte and colleagues [2] published the only other real-life com-
parative effectiveness study of rivaroxaban vs. VKA in NVAF patients.
These investigators utilized US healthcare claims from 5/2011–7/2012,
and matched 3654 rivaroxaban and 14,616 warfarin users with a
CHADS2 score ≥ 1. Their data suggested a reduction in stroke or systemic
embolism (HR= 0.77, 95%CI = 0.55–1.09) with rivaroxaban compared
with VKA therapy, although this result did not reach statistical
signiﬁcance.
There are some limitations to consider. First, a small number of pri-
mary events were observed. Second, common to administrative claims/
EMR analyses, data may contain coding inaccuracies/missing data that
can result in biases and the potential of residual confounding cannot
be excluded. Next, although sometimes used in real-world practice for
NVAF (e.g., very elderly and/or renal dysfunction), we excluded patients
receiving b15mg and/or twice daily doses of rivaroxaban because these
are not consistent with rivaroxaban's labeling for NVAF andmaybe con-
fusedwith orthopedic indicationswithin an administrative claims data-
base. Finally, to allow insights on the effectiveness of rivaroxaban
compared with VKA within the ﬁrst-year after treatment initiation,
the current analysis used only cohorts of patients with a follow-up of
≥360-days. For this reason bias in either cohort due to the exclusion of
patients with lesser follow-up cannot be ruled out.
In conclusion, this study suggests rivaroxaban is associated with fa-
vorable effectiveness in NVAF patients without previous events com-
pared to a VKA when utilized in a real-life setting. Further analysis
containing INR and effectiveness data is warranted.
Funding
This study was supported by Bayer Pharma AG.
Conﬂicts of interest
CIC has received grant funding and consulting fees from Bayer
Pharma AG, Janssen Pharmaceuticals, Boehringer Ingelheim and Pﬁzer.
MA has received consulting fees and speaker honoraria from Bayer
HealthCare, Boehringer Ingelheim, Bristol-Myers-Squibb, Daichii-
Sankyo and Pﬁzer. BE's institution (IMS Health) received funding from
Bayer for the preparation of study documents and/or the performance
of statistical analyses. TE is employee of Bayer Pharma AG.
Acknowledgments
The authors would like to acknowledge Prathamesh Pathak, who
performed the statistical analyses, and Jasmina Saric, who provided ed-
itorial support with funding from Bayer Pharma AG and Janssen Scien-
tiﬁc Affairs, LLC.Rivaroxaban N = 1039 VKA N = 1039
n (%) n (%)
20 (1.97) 37 (3.68)
172.5 155.0
0.536 (0.311–0.923, p = 0.0245)
7 (0.69) 16 (1.58)
6 (0.59) 11 (1.08)
1 (0.10) 3 (0.29)
62) 0 (0.00) 1 (0.10)
6 (0.59) 7 (0.69)
myocardial infarction; TIA = transient ischemic attack; VKA = vitamin K antagonist.
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